NCT04702425: phase 1: VOB560-MIK665 Combination First in Human Trial in Patients With Hem. Malig.
Updated: Feb 10
VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)
The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid Leukemia (AML).
VOB560 and MIK665 are selective and potent blockers respectively of the B-cell lymphoma 2 (BCL2) protein and of the myeloid cell leukaemia 1 (MCL1) protein, proteins that may protect tumor cells from undergoing cell death. VOB560 and MIK665 are designed to block the functions of the BCL2 and MCL1 proteins, so that the tumor cells that rely on these proteins undergo cell death.
Preclinical data suggest that concomitant treatment with VOB560 in combination with MIK665 induces robust anti-tumor activity.
Sponsor
Novartis Pharmaceuticals
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04702425
Official Title: A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma.
First Posted: January 8, 2021
Click here for details on ClinicalTrials.gov
Drug: VOB560
Drug: MIK665
BCL2 Inhibitor VOB560 (Code C158510)
Bcl-2 Inhibitor S65487
BCL2 Inhibitor VOB560
S 65487
S-65487
S65487
VOB 560
VOB-560
VOB560
Mcl-1 Inhibitor MIK665 (Code C133174)
Mcl-1 Inhibitor MIK665
MIK 665
MIK-665
MIK665
S 64315
S-64315
S64315
Locations
Europe
Germany
Italy
Spain
Belgium
Finland
Asia
Hong Kong
Israel
Japan
Korea, Republic of